Free tool
FAERS Monitor: Keytruda Qlex
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761467 or its brand name (Keytruda Qlex, Pembrolizumab, Berahyaluronidase Alfa-Pmph). Reports on generic versions are filed under their own applications.
Reports
56
Serious
21
38% of reports
Hospitalization
17
Death reported
5
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue5
- inappropriate schedule of product administration4
- injection site erythema4
- therapy change4
- arthralgia3
- injection site pain3
- no adverse event3
- pain3
- product use issue3
- pruritus3
- rash3
- adrenal insufficiency2
- asthenia2
- autoimmune disorder2
- cough2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2025 | 2 |
| 2026 | 54 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,103 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| therapy changeSignal | 4 | 152.8 | 59.4 | 461 |
| autoimmune disorder | 2 | 77.1 | 19.8 | 84 |
| adrenal insufficiency | 2 | 61.9 | 15.9 | 67 |
| injection site erythemaSignal | 4 | 12.1 | 4.7 | 31 |
| inappropriate schedule of product administrationSignal | 4 | 8.3 | 3.2 | 19 |
| no adverse eventSignal | 3 | 6.2 | 2.1 | 9 |
| product use issueSignal | 3 | 6.0 | 2.0 | 8 |
| injection site pain | 3 | 3.7 | 1.2 | 4 |
| pruritus | 3 | 2.9 | 1.0 | 2 |
| arthralgia | 3 | 2.7 | 0.9 | 2 |
| cough | 2 | 2.7 | 0.7 | 1 |
| rash | 3 | 2.6 | 0.9 | 2 |
| fatigue | 5 | 2.4 | 1.0 | 3 |
| asthenia | 2 | 2.0 | 0.5 | 0 |
| pain | 3 | 1.8 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.